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Abstract We reported recently that peroxisome proliferator-
activated receptor β (PPARβ) activation promotes a
calcineurin-dependent exercise-like remodelling character-
ised by increased numbers of oxidative fibres and capillaries.
As physical exercise also induces myonuclear accretion, we
investigated whether PPARβ activation alters myonuclear
density. Transgenic muscle-specific PPARβ over-expression
induced 14% increase of myonuclear density. Pharmacolog-
ical PPARβ activation promoted rapid and massive myonu-
clear accretion (20% increase after 48 h), which is dependent
uponcalcineurin/nuclear factorofactivated Tcellssignalling
pathway. In vivo bromodeoxyuridine labelling and prolifer-
ating cell nuclear antigen immunodetection revealed that
PPARβ activation did not promote cell proliferation,
suggesting that the PPARβ-promoted myonuclear accretion
involves fusion of pre-existing muscle precursor cells to
myofibres rather than cell division. Finally, we showed that
in skeletal muscle, ageing led to a down-regulation of
PPARβ accompanied by decrease of both oxidative fibre
number and myonuclear density. PPARβ pharmacological
activation counteracts, at least in part, the ageing-driven
muscle remodelling.
Keywords Skeletalmusclefibre.Myoblasts.Myogenic
response.Muscleplasticity.Calcineurin
Introduction
Adult skeletal muscle displays a remarkable capacity for
regeneration and adaptation. Skeletal myofibres represent
the largest cells in the body. They are syncitial, post-mitotic
and terminally differentiated [6, 13, 37]. Muscle fibres are
unable to proliferate but contain a pool of muscle precursor
cells (MPCs), commonly called “satellite cells”, which
reside between the basal lamina and the sarcolemma [19].
The term of muscle precursor cells is used in this report due
to the heterogeneity within the satellite cell population [40].
MPCs play crucial roles in muscle physiology, particu-
larly in muscle repair and regeneration. In response to
stress-induced myofibre damages, reparation results from
the fusion of MPCs with damaged but viable myofibres
[25, 27, 28] and regeneration from the fusion of several
MPCs within the basal lamina of the destroyed fibres for de
novo myofibre formation [25, 31, 33, 44]. MPCs prolifer-
ation is a preliminary and obligatory step of these processes
[26].
MPCs are also involved in adaptive response of skeletal
muscle to acute and chronic changes in intensity or type of
physical activity, such as muscle functional overload,
treadmill running, chronic motor nerve stimulation or
voluntary running [2, 16, 30, 32]. In these particular
conditions, MPCs proliferation is required for modifications
of myonuclear density and myofibre hypertrophy but does
not seem to be necessary for fibre twitch from faster to
slower phenotype [16, 29]. However, myonuclear accretion
is an early event of the adaptive response to aerobic training
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oxidative fibres. Furthermore, Tseng et al. showed that slow
fibres always had small volume/myonucleus regarding to
fibre diameter and that fast/oxidative fibres with high
succinate dehydrogenase (SDH) activity appeared to have
lower volume/myonucleus than fast/glycolytic fibres [39].
These differences in nuclear domain size between fibre
types were proposed to be related to the greater amount of
proteins required for oxidative metabolism, including those
implicated in mitochondrial structure and functions.
Finally, the role of MPCs in age-related muscle atrophy
is poorly documented, and conflicting observations have
been reported. It seems that ageing does not affect the
ability of MPCs to respond to various challenges even if
there might exist a delay in the proliferative responses of
MPCs from aged muscle [12]. Brack et al. reported that in
large fast muscle fibres, the decrease of myonuclei per
muscle unit preceded muscle atrophy. Authors proposed
that the age-related decrease in myofibre size may actually
be a compensatory response to an inadequate capacity for
myonuclear replacement [4]. Bruusgaard et al. reported that
aged mice display a reduction of muscle size as well as a
reduction in myonuclear number [5]. In aged mouse
muscles, authors have visualised many fragmented nuclei
suggesting increased apoptosis and have proposed that
reduction of myonuclei in old muscle could result in a
reduction of regenerative capacity of MPCs [5]. This
hypothesis is in contrast with previous observations made
in muscle inactivity experiments, in which fibre size
reduction precedes the decrease in myonuclei number [45].
We previously described the effect of peroxisome
proliferator-activated receptor (PPARβ) over-expression or
pharmacological activation in mouse tibialis anterior
(TLA), a fast/oxidative-glycolytic muscle [10, 17]. In both
models, we reported an impressive muscle remodelling
characterised by 37% hyperplasia and an increase in
oxidative fibre and capillary number [10, 18]. In PPARβ
agonist-treated animals, this remodelling takes place within
only 2 days [10]. Because of the observed oxidative and
angiogenic remodelling as well as the improvement of
metabolic profiles of PPARβ agonist-treated animals and
humans [15, 21, 36, 41], it was proposed that activation of
the PPARβ pathway mimics, at least partially, the adaptive
response of muscle to aerobic training. Muscle hyperplasia
is indicative of MPC activation [14]. Furthermore, we have
actually reported an increase of Myf5 and MyoD1 proteins
immediately after pharmacological PPARβ activation using
GW0742, also suggesting the possible activation of MPCs
[10].
As physical exercise and ageing are two physiological
situations affecting myonuclear densities, we asked how
PPARβ over-expression or pharmacological activation
affects myonuclear number in the TLA muscle from young
and aged mice. Furthermore, we investigated whether or
not MPC proliferation was required. We report here a new
striking phenotype for both PPARβ over-expressing and
PPARβ agonist-treated mice. In both cases, the number of
nuclei per unit of fibre length is significantly increased.
This augmentation of myonuclear density follows the same
kinetic as the previously described muscle oxidative and
angiogenic remodelling induced by PPARβ pharmacolog-
ical activation, starting at day 1 and being completed at day
2 of treatment [10]. Interestingly, myonuclear accretion
does not require cell proliferation. As previously described
for other PPARβ-dependent remodelling [10], the increase
in myonuclear density is prevented by inhibition of the
calcineurin pathway. Finally, we show that PPARβ is
down-regulated in aged mouse muscles and that pharma-
cological PPARβ activation, using GW0742, restores in
large part the age-related loss of myonuclei.
Materials and methods
Animals
Animals were maintained in a 12/12 h lighting cycle and
received food (UAR, France) and water ad libitum. All
experimental procedures were conducted according to
French legislation. Ten-week-old male C57BL6J (Janvier,
France) and 10 weeks and 19 month-old male B6D2
(maintained in our animal facility) were used in the various
experiments. We always used four animals per condition to
obtain statistical values. Animals were killed after the
indicated times by cervical dislocation, and tibialis anterior
muscles were harvested immediately after killing.
Animals over-expressing PPARβ specifically in skeletal
muscle were generated as previously described [18]. Briefly,
B6D2 mice harbouring a loxP–stop–loxP–PPARβ–hygrom-
ycine construction were crossed with B6D2 mice expressing
Cre recombinase under human skeletal actin (HSA) promot-
er [20]. All animals were maintained hemizygous for their
transgene. Presence of the transgenes was verified by
polymerase chain reaction (PCR) analyses of tail DNA
(REDExtract-N-Amp Tissue PCR Kit, Sigma). Animals
harbouring the two transgenes were used as PPARβ-
overexpressing mice, while animals harbouring the HSA-
Cre transgene only were used as control.
Injections
GW0742, a PPARβ-specific activator [38], was dissolved
in Dulbecco’s modified Eagle’s medium/dimethyl sulph-
oxide (DMSO) 6% (Gibco) and injected subcutaneously
once a day (9 A.M.) at 1 mg/kg. Control animals received
vehicle at 9 A.M..
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twice a day (9 A.M. and 6 P.M.) by subcutaneous injections
at 25 mg/kg in DMSO. In these experiments, GW0742 was
injected subcutaneously once a day (2 P.M.) at 1 mg/kg.
Injections of vehicle were performed at 9 A.M., 2 P.M. and
6 P.M. (Control group), 9 A.M. and 6 P.M. (GW group) and
2 P.M. (CsA group).
BrdU (Sigma) treatments were performed once a day (9 A.
M.) by intra-peritoneal injections of the compound at 100 mg/
kg in 0.9% NaCl. In these experiments, GW0742 was injected
subcutaneously once a day (2 P.M.) at 1 mg/kg. Injections of
vehicle were performed at 9 A.M.a n d2P.M. in control groups.
Immunofluorescence analysis
Tibialis anterior (TLA) muscles and duodenum were
harvested and frozen in tissue embedding medium (VWR
International) immediately after mice were killed. Ten-
micrometre cryosections were performed from the middle
part of muscle or from duodenum, placed on poly-lysine
coated slides (VWR International) and processed for
immunofluorescence analyses. Mouse monoclonal NFATc1
(7A6, sc-7294, Santa Cruz Biotechnology) and goat anti-
mouse fluorescein conjugate antibodies were both used at
1:200 dilution. For BrdU immunofluorescence, cryosec-
tions were fixed on slide according manufacturer’s protocol
and then incubated 45 min with an anti-BrdU antibody
(Anti-Bromodeoxyuridine-Fluorescein, Roche). Finally,
slides were mounted with Vectashield containing DAPI
(H-1200, Vector laboratories, Burlingame, CA, USA).
Slides were viewed under an epifluorescence microscope
connected to a digital camera with the Spot software
(Universal Imaging).
Histological and immunohistochemical analysis
TLA muscles and duodenum were harvested, fixed in 4%
paraformaldehyde (PFA) overnight, dehydrated and then
embedded in paraffin. Paraffin sections (5 μm) were used
for either BrdU or PCNA antigen detection using M.O.M.
Kit (PK-2200, Vector Laboratories). BrdU (11170376001,
Roche), PCNA (PC10, Sc-56, Santa Cruz Biotechnology)
and mouse monoclonal antibodies were used in a 1:50 and
1:100 dilution, respectively. DAB (SK-4100, Vector Labo-
ratories) served as a substrate. Nuclei were counterstained
with haematoxylin. Slides were viewed under an epifluor-
escence microscope connected to a digital camera with the
Spot software (Universal Imaging).
Single-fibre isolation
Single fibres were isolated. Both fibre length and myonu-
clear number were assessed as described by Brack et al. [4].
Briefly, TLA muscles were fixed in 4% PFA during 2 days
at room temperature. Muscles were then treated 2 h in 40%
NaOH (w/v) and agitated vigorously for 10 min. Released
fibres were washed in phosphate-buffered saline (PBS; pH
7.4) and stored at 4°C in PBS 0.05% azide.
Myonuclear density analysis
After DAPI staining, images of 40 single isolated fibres per
animal (four animals per group) were captured using a Z-
stacking procedure on a Zeiss Apotome (×10 objective),
then Z-projected using the open source ImageJ software
(Wayne Rasband, National institutes for Health). Fibre
diameters were measured at six locations over at least
500 μm length of the fibre, and all nuclei were counted
using Olympus DP-Soft software. Values obtained were
averaged to obtain mean value per fibre. Any damaged
areas of the fibres were not analysed.
Sodium dodecyl sulfate polyacrylamide gel electrophoresis
and Western blot
Total TLA lysates from the mice treated with GW0742 or
vehicle alone (DMSO) were prepared, electrophoresed and
blotted on polyvinylidene difluoride membrane. Subcellular
fractionation of TLA muscles was performed using the
Qproteome™ Cell Compartment Kit (Quiagen) according
to manufacturer’s instructions. The following antibodies
were used at the indicated dilutions for immunodetection:
Pan A calcineurin (AB1695, Chemicon International)
1:1,000, polyclonal anti P85 (PI3K subunit) from rabbit
(06-496, Upstate, Lake Placid, NY, USA) 1:1,000, poly-
clonal anti CREB from rabbit (kind gift of Dr. M. Montminy,
San Diego, USA) 1:2,000, polyclonal anti Rho GDIa from
rabbit (A-20, sc-360, Santa Cruz Biotechnology) 1:500,
polyclonal anti acetyl-histone 3 from rabbit (06-599,
Upstate, Lake Placid, NY,USA) 1:1,000, monoclonal
NFATc1 from mouse (7A6, sc-7294, Santa Cruz Biotech-
nology) 1:200, monoclonal NFATc3 from mouse (F-1, sc-
8405, Santa Cruz Biotechnology) 1:200, peroxidase-coupled
anti-rabbit and peroxidase-coupled anti-mouse secondary
antibodies (Vector Laboratories) 1:5,000.
Quantitative reverse transcription PCR
Reverse transcription was performed using 0.2 μg of total
RNA from muscle of 10 week-old and 19 month-old
C57Bl6 mice (five animals per group), a Core kit (RT-
RTCK-03, Eurogentec) according to manufacturer’s in-
struction and a mix of random primers (9 mers) and
oligodT. qPCR was performed on SDS7900HT (Applied
Biosystem) using Mesagreen qPCR kit for SYBR (Euro-
gentec) and the following primers:
Pflugers Arch - Eur J Physiol (2009) 458:901–913 903PPARβ:5 ′-AGATGGTGGCAGAGCTATGACC-3′;
5′-TCCTCCTGTGGCTGTTCC-3′.
Catalase: 5′-GGATCCTGACATGGTCTGGG-3′;5 ′-
TGGAGAGACTCGGGACGAAG-3′.
PDK4: 5′-GCATTTCTACTCGGATGCTCAATG-3′;
5′-CCAATGTGGCTTGGGTTTCC-3′.
36B4: 5′-TCCAGGCTTTGGGCATCA-3′;5 ′-
CTTTATCAGCTGCACATCACTCAGA-3′.
Data were all normalised using 36B4 as housekeeping
gene.
Statistical analysis
The effect of the duration of treatment was performed
by a one-way analysis of variance (ANOVA) test. Two-
way ANOVA tests were performed for comparisons
between groups (age and treatment; age and trans-
genicity). When significant changes were observed in
ANOVA tests, Fisher’s protected least significant differ-
ence post hoc test was applied to locate the source of
significant differences. When two groups were com-
pared, we used a Student’s t test. Analyses were
performed with Stat’View Abacus Concept version 5.
Hierarchical ascendant classifications were performed for
the determination of fibre groups according to nuclei/mm
of fibre length. Results are presented as means±SD with
significance accepted when p<0.05.
Results
PPARβ pathway activation promotes an increase
in myonuclear density in TLA muscle
The effects of PPARβ over-expression on myonuclear
density were first investigated by quantification of myonu-
clear number per millimetre of fibre length in diamidino-2-
phenyl-indole (DAPI)-stained isolated fibres, prepared from
TLA muscle of adult B6D2 PPARβ transgenic mice and
control littermates (Tg and Ct; Fig. 1a). These experiments
revealed that muscle-specific PPARβ over-expression leads
to a 14% increase of nuclei number per millimetre of fibre
length (92±1.32, n=160 fibres for controls versus 105±3.2,
n=160 fibres for PPARβ transgenic mice, p=0.003).
Using ascendant hierarchical classification, we defined
three groups of myofibres, i.e. those containing less than
85nuclei/mm(F<85), those containing a number of nuclei
comprised between 85 and 100 nuclei/mm (85<F<100)
and those containing more than 100 nuclei/mm (F>100).
A ss h o w ni nF i g .1b, PPARβ over-expression induced
major changes in myofibre distribution in these three
groups with reduction of myofibre numbers in both the
F<85 (31% to 10%) and 85<F<100 (41% to 35%)
groups, while the number of fibres in the F>100 group
is notably increased (28% to 55%).
We then investigated the effects of pharmacological
PPARβ activation on myonuclear density by treating
10-week-old C57Bl6 male mice with GW0742, a PPARβ-
specific agonist [38]. The number of myonuclei/mm fibre
length was determined at increasing times after GW0742
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Fig. 1 Muscle-specific PPARβ over-expression promotes an increase
of myonuclear density. a Representative isolated DAPI-stained fibres
harvested from tibialis anterior of 10-week-old control (Ct) and
PPARβ transgenic (Tg) B6D2 mice. Global myonuclear density is
indicated as myonuclei number per millimetre of fibre length (n=160,
four animals per group, 40 fibres per animal). b Distribution of
myofibres population in TLA from control and PPARβ overexpress-
ing mice. Myonuclei in isolated DAPI-stained fibres (n=160, four
animals per group, 40 fibres per animal) harvested from tibialis
anterior of 10-week-old control (Ct) and PPARβ transgenic (Tg)
B6D2F1 mice were quantified and pooled using ascendant hierarchi-
cal classification in three groups of fibres containing (1) less than 85
nuclei, (2) from 85 to 100 nuclei and (3) more than 100 nuclei/mm of
fibre length. Percentage of each group, mean number of nuclei in each
group (Mean) and standard deviation (s.d.) are reported for control
(Ct) and PPARβ transgenic (Tg) mice
904 Pflugers Arch - Eur J Physiol (2009) 458:901–913or vehicle injections. We first noticed a significant strain
difference concerning the myonuclear density (92±1.32
and 86±1.40, in B6D2 and C57Bl6 mice, respectively) as
well as the distribution in the three predefined groups
between B6D2 and C57Bl6 mice (compare Ct in Fig. 1bt o
Fig. 2b). As expected, vehicle treatment did not affect
myonuclear density nor distribution in the three predefined
groups of fibres (not shown). On the contrary, PPARβ
activation promoted a fast increase in myonuclear density
with an 11% (p<0.0001) increase after 1 day and a maximal
augmentation of 20% (p<0.0001) reached after 2 days of
treatment (Fig. 2a). Classification of fibres in the three
predefined groups revealed that, as previously observed in
PPARβ transgenic mice, pharmacological PPARβ activation
resulted in time-dependent and notable changes in fibre
group distribution in favour of fibres with a high myonuclear
density. This shift towards the F>100 group is progressive
from 8% to 34% after 1 day and to a maximum of 62%
reached after 2 days, with a parallel decrease of percentage
of fibres in both F<85 group (47% to 28% after 1 day and to
15% after 2 days) and 85<F<100 group (45% to 38% after
1 day and to 23% after 2 days; Fig. 2b).
Pharmacological PPARβ activation does not promote cell
division in TLA muscle
The fast and important increase in myonuclear density as
well as hyperplasia suggests major events of MPC
activation and fusion to myofibres. However, the quickness
of myonuclear accretion in response to PPARβ activa-
tion argues against a process requiring cell proliferation.
To investigate directly the effect of PPARβ activation
on cell proliferation in TLA muscle, we explored by
immunochemistry the expression of a well-known
mitosis marker, the proliferating cell nuclear antigen
(PCNA), in muscles from animals receiving or not
GW0742 for various times. Sections of the duodenum
from control animals were used as positive control and
displayed, as expected, an important labelling in the
crypts (Fig. 3a). In contrast, nearly no PCNA-positive
myonuclei were detectable in sections from control
animals (Fig. 3b). As shown in Fig. 3,P P A R β activation
did not increase the number of PCNA-positive myonu-
clei, whatever the period of treatment with GW0742
was, i.e. 5 h (Fig. 3c ) ,2 4h( F i g .3d), or 48 h (Fig. 3e, f).
However, after 48 h of PPARβ agonist treatment,
several fibres with centrally located myonuclei can be
observed as a mark of myonuclear accretion (Fig. 3e
and f). These results suggest that PPARβ-promoted
myonuclear accretion did not involve proliferation of
MPCs. Finally, we did detect some PCNA-positive cells
but almost only in blood vessels (Fig. 3d, h–ja th i g h
magnification).
To confirm these observations, bromodeoxyuridine
(BrdU) incorporation into DNA was used. In vivo BrdU
labelling technique allows identification of MPCs that have
proliferated, migrated and either incorporated into existing
myofibres or having been implicated in the formation of
new fibres [16, 35]. BrdU incorporation into DNA was
determined by two different methods, indirect immunoflu-
orescence on cryosections and immunochemistry on
paraffin-embedded sections. As shown in Fig. 4a, b,
sections from the duodenum of control animals that
received for 1 (Fig. 4b) or 2 days (Fig. 4a) daily injections
of BrdU validated the method to follow cell proliferation in
vivo, as BrdU-positive cells are detected both in crypts,
where the cells are proliferating, and in the lower parts of
the villi that contain epithelial cells, which have proliferated
in the crypts (Fig. 4b) and then migrated during their
differentiation towards the villous apex (Fig. 4a). Data
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Fig. 2 PPARβ pharmacological activation induces an increase of
myonuclear density. a Quantification of myonuclei number in isolated
DAPI-stained fibres (n=160, four animals per group, 40 fibres per
animal) harvested from tibialis anterior of 10-week-old C57Bl6 mice
for different times of treatment with vehicle (Ct)o rP P A R β agonist
GW0742 (1 day (1d), 2 days (2d) and 4 days (4d)). *p<0.001,
different from vehicle-treated group (Ct); pound sign p<0.01, different
from 1 day treated animal group (1d). b Distribution of myofibres
population counted in a using the same classification as in Fig. 1b.
Percentage of each group, mean number of nuclei in each group
(Mean) and standard deviation (s.d.) are reported for each period of
treatment with GW0742
Pflugers Arch - Eur J Physiol (2009) 458:901–913 905presented in Fig. 4 confirmed that PPARβ-promoted
muscle remodelling does not implicate cell proliferation as
the number of BrdU-positive nuclei remained very low in
muscle from animals treated for 2 days with GW0742. Less
than 1% of nuclei were BrdU-positive, and no significant
difference was found compared to muscles from untreated
animals. Furthermore, as previously observed, several
myofibres containing central nuclei can be evidenced in
muscles from animals treated for 48 h with GW0742
(Fig. 4c, e, f). Interestingly, these nuclei remained BrdU-
a
e f
b
d c
h g
i j
Fig. 3 GW0742-promoted
myonuclear remodelling is in-
dependent of cell proliferation in
tibialis anterior. Immunohisto-
chemical localization of PCNA,
a well-known mitotic marker, in
a section of duodenum as posi-
tive control, b, g section of TLA
muscles from vehicle-treated
animals, c–j sections of TLA
muscles from animals receiving
GW0742 for various times: c,
h 5h ,d, i 24 h, e, f, j 48 h. Note
the important labelling in the
crypts and the quasi absence of
positive myonuclei in both
control and GW0742-treated
animals. PCNA signals were
often detected in blood vessels
(arrows in d, h–j) but rarely in
myonuclei (arrows in c). Finally,
note the elevated number of
centrally located nuclei
(arrowhead in e, f). Scale bars,
50 μm
906 Pflugers Arch - Eur J Physiol (2009) 458:901–913negative. As central nuclei are marks of the fusion of MPCs
to fibres and/or newly formed myofibres, these observa-
tions also strongly support the conclusion that myonuclear
accretion and fibre hyperplasia promoted by PPARβ
activation took place without MPC proliferation.
Positive effects of PPARβ activation on myonuclear
density are dependent of the calcineurin/NFAT pathway
We previously provided evidences that the active calci-
neurin pathway is required for the myogenic and angio-
genic responses to PPARβ activation in the adult mouse
[10]. To test whether an active calcineurin pathway was
required for the PPARβ-promoted myonuclear accretion,
we explored the effects of co-administration of cyclospor-
ine A (CsA), a potent inhibitor of calcineurin/nuclear factor
of activated T-cells (NFAT) pathway, on TLA myonuclear
density in mice treated by GW0742 for 2 days.
As shown in Fig. 5a, b, CsA administration alone neither
affected the myonuclear density nor the distribution in the
three defined fibre groups. On the contrary, CsA adminis-
tration totally blunted the PPARβ-dependant increment of
global myonuclear density (from 86 to 104 nuclei/mm in the
absence and to 87 nuclei/mm in presence of CsA; Fig. 5a).
Calcineurin inhibition strongly reduced the redistribution of
myofibres towards the group with the highest myonuclear
density (shift from 8% to 62% in the absence of CsAversus
shift from 8% to 20% when CsA was co-administrated;
Fig. 5b).
Our data also indicated that in TLA muscle, GW0742
treatment did not promote an increase of calcineurin at the
protein level (Fig. 6a) but rather provokes an induction of
a b
c d
e f
Fig. 4 GW0742-promoted myonuclear remodelling does not require
cell division in tibialis anterior. Mice were injected with BrdU and or
not with GW0742. Duodenum (a, b) or TLA muscle (c–f) harvested
from 24 h (b)o r4 8h( a, c–f) post GW0742 treatment, were either
frozen in tissue-embedding medium or fixed, dehydrated and
embedded in paraffin. Frozen sections on slides were stained with
anti-BrdU antibody coupled to fluorescein (a, c, e) and mounted using
Vectashield containing DAPI as described in “Materials and methods”.
Positive cells are detected in blood vessels, and very few myonuclei
are labelled (c, e). Arrowheads indicate myofibres with central nucleus
(c, e). Paraffin sections were stained with anti-BrdU antibody (b, d, f)
as described in “Materials and methods”, and nuclei were counter-
stained with haematoxylin. Very few myonuclei are labelled (d, and
arrow in f); on the contrary, a large number of myofibres with one or
more central nuclei are visible (d, e, f). Note the increased BrdU
labelling in the duodenum sections between 24 h (b) and 48 h (a)o f
the BrdU pulse. Scale bar, 50 μm
Pflugers Arch - Eur J Physiol (2009) 458:901–913 907its phosphatase activity as attested by the rapid nuclear
translocation of nuclear factor of activated T cells C1 and
C3. Indeed, enhanced NFATc1 nuclearization can be
evidenced as soon as 5 h after GW0742 treatment
(Fig. 6b, c). It remained high at 24 h of treatment and
returned to control value after 48 h (Fig. 6c). NFATc3
nuclearization can be evidenced after 24 h of PPARβ
agonist treatment, and it returned to control values after
48 h of treatment.
Ageing promotes a decrease in myonuclear density, while
PPARβ agonist treatment restores a juvenile phenotype
Myonuclear density is negatively regulated by ageing [4,
5]. In order to explore a possible role of PPARβ in this a
process, we first investigated the effect of ageing on
PPARβ expression by comparing the amounts of the
corresponding mRNA in mouse TLA from adult (10-week-
old) and aged (19-month-old) mice. As shown in Fig. 7,
PPARβ mRNAwas down-regulated by more than 30% (p=
0.03, n=5) in aged mouse muscles when compared to
young mouse muscles. To check whether the decreased
expression of PPARβ impacts on gene regulation, we also
quantified mRNA for two PPARβ-target genes, namely
catalase, that plays a crucial role in the protection against
oxidative stress [23], and pyruvate dehydrogenase kinase 4
(PDK4) that is involved in metabolic regulations [7]. These
experiments revealed that in aged mice, both genes were
down-regulated (40%, p=0.01, and 75%, p=0.001 for
catalase and PDK4, respectively; Fig. 7a). However,
PPARβ pathway remains active in aged mice as 4 days of
GW0742 treatment promoted an up-regulation of these
target genes (1.76-fold, p=0.034, and 6.19-fold, p=0.047
for catalase and PDK4, respectively; Fig. 7b). As expected,
GW0742 treatment did not modify PPARβ expression.
The effect of ageing on myonuclear density was next
investigated in TLA muscles from young and aged B6D2
control mice (Ct and 19Ct in Fig. 8a, b). As shown in
Fig. 8a and in agreement with other reports [5], global
myonuclear density was slightly but significantly lower in
aged mice when compared to young adult animals (−5%,
p=0.0057). The effect of ageing on myonuclear density is
further evidenced when evaluating the fibre distribution
profile in the previously defined groups. In aged mice, the
number of fibres in the F<85 group was increased by 1.35-
fold (31% to 42%), whereas the fibre numbers in F>100
and 85<F<100 groups were reduced 1.22- and 1.17-fold,
respectively compared to those of young mice (Fig. 8b).
Furthermore, the mean value in the F<85 group seems to
be lower in aged animals than in young adult animals,
whereas other mean values remain stable (Fig. 8b).
To explore a possible beneficial action of PPARβ
pathway activation on myonuclear density, we next inves-
tigated the effects of muscle specific PPARβ over-
expression on the ageing-related loss of myonuclei. In
elderly PPARβ transgenic animals, we have observed a
significant reduction in global myonuclear density (−7%,
p<0.0052) and a shift towards fibres that contain fewer
nuclei (Tg and 19Tg in Fig. 8a, b) when compared to their
younger counterparts. Despite this reduction, global myo-
nuclear density in aged transgenic mice remained in the
same order of value than that found in young untreated
mice (compare CT and 19Tg in Fig. 8a). Furthermore, the
percentage of fibres in the F>100 group remained
significantly higher in old transgenic animals than in
control young animals (F>100=28% and 46% in CT and
19Tg, respectively. Fig. 8b). Finally, we studied the effects
of pharmacological PPARβ activation on myonuclear
density in young and old B6D2F1 mice (GW and 19GW
in Fig. 8a, b). In young control mice, 4 days treatment with
a.
80
85
90
95
100
105
110
Ct CsA 2d+CsA 2d
*
N
u
c
l
e
i
 
/
 
m
m
b.
Mean 76 92 102 75 92 105 78 91 115 75 92 106
s.d. 7 4 2 8 4 4 4 3 13 7 4 4
Ct CsA 2d 2d + CsA
%
 
o
f
 
f
i
b
e
r
s 47 45
8
45 44
11
15
23
62
44
36
20
8
5
 
<
 
F
 
<
 
1
0
0
8
5
 
<
 
F
 
<
 
1
0
0
8
5
 
<
 
F
 
<
 
1
0
0
8
5
 
>
 
F
8
5
 
<
 
F
 
<
 
1
0
0
1
0
0
 
<
 
F
8
5
 
>
 
F
1
0
0
 
<
 
F
8
5
 
>
 
F
1
0
0
 
<
 
F
8
5
 
>
 
F
1
0
0
 
<
 
F
0
10
20
30
40
50
60
70
Fig. 5 Positive effects of PPARβ on myonuclear density are
calcineurin dependent. a Quantification of nuclei number in isolated
DAPI-stained fibres harvested from tibialis anterior of 10-week-old
C57Bl6 animals (n=160, four animals per group, 40 fibres per
animal), treated 2 days with vehicle (Ct), cyclosporine A (CsA),
PPARβ agonist GW0742 (2d)o rP P A R β agonist GW0742 and
cyclosporine A (2d+CsA). *p<0.01, different from Ct, CsA and
2d+CsA groups. b Distribution of myofibres population counted in
a using the same classification as in Fig. 1b. Percentage of each
group, mean number of nuclei in each group (Mean)a n ds t a n d a r d
deviation (s.d.) are reported for each treatment
908 Pflugers Arch - Eur J Physiol (2009) 458:901–9130
0,2
0,4
0,6
0,8
1
1,2
1,4
PPARβ Catalase PDK4
* *
#
m
R
N
A
 
i
n
 
a
r
b
i
t
r
a
r
y
 
u
n
i
t
a
0
1
2
3
4
5
6
7
8
9
10
11
PPAR β Catalase PDK4
m
R
N
A
 
i
n
 
a
r
b
i
t
r
a
r
y
 
u
n
i
t
*
*
b
Fig. 7 Ageing reduces expression of PPARβ, catalase and PDK4
mRNAs. a Quantification of PPARβ, catalase and PDK4 using mRNAs
f r o mm u s c l e so f1 0 - w e e k - o l d( white bar) and 19-month-old (dark bar)
mice (five animals per group) and qPCR analyses as described in
“Materials and methods”.* p<0.05, different from 10-week-old mice
group; pound sign p<0.005, different from 10-week-old mice group. b
Quantification of PPARβ, catalase and PDK4 using mRNAs from
muscles of 20-month-old mice treated (cross-hatched bar)o rn o t( dark
bar) during 4 days with GW0742 (four animals per group) and qPCR
analyses as described in “Materials and methods”.* p<0.05, different
from 20-month-old untreated mice group. Results in a and b were
normalised using 36B4 as housekeeping gene
b. DMSO 5H GW 5H CsA + GW 5H
c.
Acetylated
H3 Histone
NFATC1
Rho
Creb
CNI
DMSO 5h GW 5h DMSO 24h GW 24h GW 48h
NFATC3
CN I C N I CN I CN I
a.
DMSO 5H GW 2H GW 5H GW 8H GW 24H
Calcineurin
P85
Fig. 6 GW0742 induces calci-
neurin A-dependent NFAT
nuclearization. a Calcineurin
and P85 Western blot analysis
after control treatment (DMSO
5H) or different times of
GW0742 treatment (2, 5, 8, and
24 h). P85 is used as loading
control. b Immunohistochemical
localization of NFATc1 using
cryosections of TLA muscles
from mice treated 5 h with
DMSO (DMSO 5H), GW0742
(GW 5H) or cyclosporine A and
GW0742 (CsA+GW 5H). Note
the increased NFATc1 nucleari-
zation only in GW 5H-treated
animals. c TLA muscles from
mice treated 5 or 24 h with
DMSO (DMSO 5h, DMSO 24h),
or treated 5, 24, or 48 h with
GW0742 (GW 5h, GW 24h, GW
48h) were used for subcellular
fractionation in cytoplasmic (C),
nuclear (N) and insoluble-
chromatin-associated (I) proteins
and subsequent Western blot
analysis. Note the increased nu-
clear localization of NFATc1
and NFATc3 in response to
PPARβ activation. CREB (nu-
clear), Rho GDIα (cytoplasmic)
and acetylated histone H3 (H3,
Chromatin associated) antibod-
ies were used to evaluate the
purity of each fraction. Scale
bar, 50 μm
Pflugers Arch - Eur J Physiol (2009) 458:901–913 909GW0742 resulted in an increase (14%, p=0.048) in the
global myonuclear density (Fig. 8a) and redistribution of
fibres in favour of the F>100 group (28% to 67%, Fig. 8b).
This augmentation is similar to that observed in PPARβ-
over-expressing transgenic mice (compare CT, TG and GW
in Fig. 8a) but is less important than the observed 20%
increase in young C57Bl6-treated mice (Fig. 2a). Interest-
ingly, in aged B6D2F1 mice (19GW), 4 days administration
of PPARβ agonist led not only to a 9% (p=0.0318) increase
in the myonuclear density (compare 19Ct and 19GW in
Fig. 8a) but also to a redistribution of fibres in the group
which contained more than 100 nuclei/mm (F>100; 23% to
38%; Fig. 8b). The percentage of fibres in the F<85 group
was reduced (42% to 25%), whereas the 85<F<100 group
remained stable (Fig. 8b). Interestingly, treatment allowed
aged mice to reach similar global myonuclear density as 10-
week-old control mice (compare 19GW and Ct in Fig. 8a),
almost the same fibre distribution profile (Fig. 8b) and
slightly better mean values in the three groups, indicating
that PPARβ activation could compensate the age-related loss
of myonuclei.
Ageing promotes a decrease in oxidative myofibre number,
while PPARβ agonist treatment restores a juvenile
phenotype
To characterise the impact of ageing on fibre type
composition and the effects of PPARβ activation on this
parameter, we used cross-sections around mid-portion of
the TLA muscles from 10-week-old and 22-month-old
animals treated or not for 4 days with GW0742 for in situ
staining of succinate dehydrogenase activity, which is a
marker of mitochondrial complex II content. In accordance
with our previous observations [10], TLA from young adult
C57Bl6 mice contains about 46% of SDH-positive fibres
and 54% of SDH-negative fibres, and GW0742 treatment
promotes an increment of the oxidative phenotype charac-
terised by increased proportion of SDH-positive fibres
(Table 1). TLA from aged animals displayed a less oxidative
phenotype with decreased proportion of SDH-positive fibres
(39.3 % in aged versus 46.3% in young animals). Interest-
ingly, 4 days of GW0742 administration promoted an
increase of SDH-positive fibre proportion in aged mouse
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observed in young untreated animals (Table 1). This
PPARβ-promoted increment of oxidative capabilities of
TLA from aged animals was then confirmed by the
determination of citrate synthase (CS) activity as a marker
of the oxidative metabolism and lactate dehydrogenase
(LDH) activity as a marker of glycolytic metabolism. These
experiments showed that, after 4 days of PPARβ agonist
treatment, the CS specific activity was increased by 16.7%
(p=0.002, n=4), while the LDH-specific activity remained
unchanged (p>0.5, n=4). Comparable effects were previ-
ously reported in PPARβ transgenic animals [18].
Discussion
We previously reported that PPARβ activation or over-
expression in mice induces striking skeletal muscle oxida-
tive and angiogenic remodelling [10, 18]. We report here a
new phenotype in both PPARβ transgenic mice and
PPARβ agonist-treated mice, consisting in massive activa-
tion, recruitment and fusion of MPCs to both pre-existing
and newly formed myofibres. Fusion of such a large
number of myonuclei may represent a key event in the
PPARβ-promoted oxidative muscle remodelling.
This newly described PPARβ-promoted phenotype is
remarkable in magnitude and quickness. First, in
B6D2F1 mice, muscle-specific PPARβ over-expression
or pharmacological activation induced a 14% increase in
myonuclear density when compared to control animals.
This myonuclear density increment is even more
pronounced in GW0742-treated C57Bl6 mice which
display a 20% augmentation. Taking into account that
in the TLA of C57Bl6, PPARβ agonist treatment also
leads to a muscle hyperplasia corresponding to the
generation of 600 new myofibres [10], it can be
estimated that PPARβ activation resulted in addition of
about one million of new myonuclei to each muscle.
Furthermore, these events of MPC activation, recruitment
a n df u s i o nc o u l da l s oh a p p e ni no t h e rm u s c l e s ,r e s u l t i n gi n
addition of several millions of new myonuclei per animal.
The quickness of myonuclear accretion after PPARβ
administration is also very impressive. In both C57Bl6
and B6D2F1, GW0742 treatment promoted an increase in
myonuclear density that was already detectable at day1
a n da c h i e v e da td a y2( F i g .2). This process takes place in
the same time frame that we have already determined for
the PPARβ-promoted myogenic/angiogenic muscle
remodelling [10]. Analysis of the fibre distribution
depending on their myonuclear content per millimetre of
fibre length (F<85; 85<F<100; F>100) allowed a better
description of the effects of PPARβ pathway activation.
Both PPARβ over-expression and its pharmacological
activation highly increased the number of fibres that
contain more than 100 nuclei/mm fibre length (Fig. 1b
and 2b). Furthermore, in GW0742-treated animals, we
observed a time-dependent shift from the two classes of low
myonuclear density fibres towards high myonuclear density
fibres. Indeed, in C57Bl6, the fibres that contain less than 100
nuclei (F<85 and 85<F<100) represent 93% of the
myofibres before the treatment, 66% after 1 day of treatment,
and only 38% after 2 days of treatment (Fig. 2b). Since these
fibres did not disappear, the most probable scenario is a rapid
and progressive recruitment and fusion of MPCs to pre-
existing and newly formed fibres.
Another remarkable feature of the PPARβ-promoted
myonuclear accretion is the finding that proliferation of
MPCs is not required for such a remodelling (Figs. 3
and 4). This is in contrast with other pathological or
physiological situations leading to muscle remodelling,
such as adaptation to exercise, overload or muscle
regeneration, in which a critical and obligatory step of
MPCs proliferation has been established [16, 26]. How-
ever, it should be noted that in these situations, muscle
remodelling takes place within weeks and often follows
muscle damage, whereas PPARβ-promoted muscle
remodelling is achieved in 2 days without any histological
sign of fibre deterioration. All our observations argue in
favour of a model, in which the PPARβ pathway activates
ap o o lo fM P C st h a ta r e“committed” to differentiate and
able to fuse to fibres omitting the obligate step of
proliferation. Existence of such cells has already been
s u g g e s t e db yo t h e r s[ 1, 11, 24, 43].
The central role of the calcineurin/NFAT pathway in the
maintenance of fibre type composition and in muscle
adaptation to physical exercise has been well documented
Table 1 Ageing promotes a decrease of TLA oxidative fibre proportion, while PPARβ agonist treatment restores a juvenile phenotype
Age in month 2.5 months 22 months
C57Bl6 Mice Control GW96h p value Control GW96h p value
SDH positive (%) 46.4±1.3 54.6±1.9 1.5E−05 39.3±1.4 47.6±2.4 0.0067
SDH negative (%) 53.6±1.3 45.4±1.9 1.5E−05 60.7±1.4 52.4±2.4 0.0067
In situ staining of succinate dehydrogenase activity using cross-sections around mid-portion of the TLA muscles from 10-week-old and 22-month-
old animals treated or not for 4 days with GW0742
Pflugers Arch - Eur J Physiol (2009) 458:901–913 911(for review, see [3]). The calcineurin pathway has also been
associated with MPC activation [8, 22, 34]. As cyclospor-
ine A administration abolished both myogenic and angio-
genic responses to PPARβ activation, we previously
proposed that active calcineurin pathway is required for
PPARβ-promoted muscle remodelling [10]. Data presented
here reinforce this model as demonstrating that treatment of
mice with GW0742 did not affect calcineurin A expression
but induced calcineurin A activation as shown by the rapid
nuclearization of both NFATc1 and NFATc3 in TLA
(Fig. 6). The finding that CsA administration impaired the
PPARβ-dependent increase in global myonuclear density
(Fig. 5a) as well as the redistribution of myofibres in the
three defined fibre groups (Fig. 5b) strongly suggests that
the calcineurin/NFAT pathway is involved directly in the
PPARβ-promoted myonuclear accretion. Further work is
required to fully characterise the signalling cascade that
follows PPARβ-promoted NFAT activation.
A characteristic of ageing muscle is fibre atrophy and
loss of myonuclei [4, 5]. In particular, the regression in
myonuclear content seems to be a key event in the process
of age-related muscle atrophy. Our data confirmed that
ageing leads to a reduction in global myonuclear density
and to a poor fibre distribution profile (Fig. 8a, b).
Furthermore, ageing results in a reduction of TLA muscle
oxidative capabilities (Table 1), down-regulation of PPARβ
expression and transcriptional activity (Fig. 7). As we have
demonstrated that PPARβ pathway activation promotes
both oxidative phenotype [10, 18] and myonuclear accre-
tion (Figs. 1 and 2), it is tempting to speculate that PPARβ
down-regulation observed in muscle from aged animals is
directly involved in the age-related reduction of both
myonuclear density and oxidative phenotype in TLA. The
findings showing that PPARβ over-expression or pharma-
cological activation (Fig. 8a, b and Table 1) counteract, at
least in part, the effects of ageing on these parameters
suggest that PPARβ activation could exert preventive or
curative effects on both age-related muscle atrophy and
reduction of oxidative phenotype.
The effect of such import of new genetic material on the
functional and metabolic abilities of muscle cells of treated
animals remains to be determined. However, it may
represent the basis for the rapid muscle plasticity and
adaptation to aerobic exercise, possibly allowing a reprog-
ramming of muscle cells toward a more oxidative pheno-
type, through an increased coding efficiency for contractile
proteins and genes involved in fatty acid oxidation and
mitochondrial biogenesis [39]. This hypothesis could
explain the role of PPARβ induction after various types
of physical training [9, 18, 42]. Finally, our data indicate
that, in addition to its beneficial effects on metabolism,
PPARβ agonists may represent a therapeutic approach for
the treatment of age-related muscle atrophy.
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